Lynozyfic is one of two bispecific antibodies Regeneron hopes will lift its oncology business. Meanwhile, IGM is the latest struggling biotech to agree to a buyout deal from Concentra.
Regeneron bispecific approved for myeloma; Concentra to buy IGM
HOT NEWS
Human Abuse Potential Studies
Download this scientific journal to learn more. Learn more about human abuse potential (HAP) studies…
تُظهر الدراسة أن وجبة الإفطار الغنية بالجوز من الممكن أن تساعد في تعزيز قوة دماغك
California Walnut كما أظهر بحثٌ جديد أن تناول الجوز في وجبة الإفطار يمكن أن يحسّن…
Arab Newswire Provides Press Release Distribution in Arabic
Arab Newswire - Press release distribution to media in MENA/GCC Regions Newswire expands reach with…